# Maternal hsa-miR-423-5p associated with the cognitive development of babies in pregnant women without mental disorders

## TL;DR

This study found that higher levels of a specific microRNA in pregnant women are linked to better cognitive development in their babies at 3 months old.

## Contribution

The study identifies hsa-miR-423-5p as a potential prenatal biomarker for infant cognitive development.

## Key findings

- Maternal hsa-miR-423-5p levels during pregnancy correlate with infant cognitive scores at 90 days.
- Each increase in miR-423-5p is associated with a 2.40-point rise in cognitive development scores.
- The miRNA could serve as a prenatal biomarker for early intervention planning.

## Abstract

MicroRNAs (miRNAs) are small non-coding RNAs capable of regulating gene expression post-transcriptionally. MiRNAs are recognized as key regulators of diverse biological and developmental processes. During the pregnancy–puerperal cycle, numerous changes occur in the female body for the formation, growth, and development of the baby. After birth, there is a critical period in child development, as rapid gains in the physical, cognitive, and socio-emotional domains constitute the “building blocks” of children’s later growth.

The aim of this study was to investigate the association between maternal expression of hsa-miR-423-5p during the first and second trimesters of pregnancy and neurocognitive development at 90 days of life in infants. Methods: This is a longitudinal study included in a population-based cohort study, carried out in a city in southern Brazil. The Bayley III was used to assess the babies’ cognitive development. Blood samples from mothers were obtained for RNA extraction from serum and analysis of miRNA expression by qRT-PCR.

In total, 87 dyads (mother–baby) were included. The average gestational age was 15.86 weeks (SD ± 5.55). An association of maternal miRNA with infant cognitive development was found; as maternal miR-423-5p increases, infants’ cognitive development increases by 2.40 (95% CI 0.37; 4.43, p = 0.021) points at 3 months of age.

In this context, it is suggested to use this miRNA as a biomarker of child neurocognitive development detectable in the prenatal period, thus allowing the planning of early interventions.